Related by context. All words. (Click for frequent words.) 72 isoform selective 70 mediated inhibition 68 JAK2 inhibitor 68 vivo potency 67 chemopreventive agent 67 PI3K/mTOR 67 humanized monoclonal 66 immune modulatory 66 Aplidin 66 fibrotic disease 66 antisense inhibitors 66 investigational humanized monoclonal antibody 66 potently inhibit 66 kinase inhibition 66 selective modulator 66 diagnostic biomarker 66 p# inhibitor 65 NV1FGF 65 tumorigenicity 65 generation purine nucleoside 65 anticancer compound 65 novel peptide 65 Ceflatonin 65 histone deacetylase HDAC 65 small molecule tyrosine 65 Squalamine 65 Vidaza azacitidine 65 proteasome inhibitor 65 Preclinical studies suggest 65 MAGE A3 ASCI 65 inhibit angiogenesis 65 BrachySil TM 65 vascular disrupting agent 65 mTOR inhibition 65 BRAF inhibitors 65 targeted antifolate 65 liposomal formulation 65 huC# DM4 65 aurora kinase 64 mitogen activated ERK kinase 64 thrombin receptor 64 IL# PE#QQR 64 TLK# 64 vidofludimus 64 NS#/#A protease 64 Factor VIIa 64 mertansine 64 ganaxolone 64 compound AEZS 64 Guanilib 64 humanized monoclonal antibodies 64 somatostatin receptor 64 IAP inhibitor 64 A3 adenosine receptor 64 MEK inhibitors 64 Sudhir Agrawal D.Phil 64 ERK signaling 64 Tß4 64 oral prodrug 64 PI3K inhibitors 64 Onconase 64 intranasal delivery 64 protein tyrosine phosphatase 1B 64 Panzem 64 systemically administered 64 selectively inhibited 64 small molecule activators 64 myeloproliferative diseases 63 kallikrein 63 cediranib 63 cannabinor 63 Enzastaurin 63 Zybrestat 63 LEP ETU 63 ATL# [001] 63 sunitinib Sutent 63 immune modulating 63 histone deacetylase inhibitor 63 AEG# 63 immuno modulatory 63 Aviptadil 63 non nucleoside 63 fosbretabulin 63 CDK inhibitor 63 Mipomersen 63 PPARγ 63 BN# [002] 63 small molecule activator 63 histone deacetylase HDAC inhibitor 63 Personalized Immunotherapy 63 siRNAs targeting 63 antiangiogenic drugs 63 targeting CD# 63 RNA antagonist 63 targeted radiotherapeutic 63 inhibitor ARRY 63 depsipeptide 63 mGluR2 NAM 63 molecular biomarkers 63 Tasimelteon 63 neuroprotectant 63 selective inhibition 63 JAK inhibitor 63 vascular disrupting agents 63 delafloxacin 63 HepDirect prodrug 63 NEUGENE R 63 Fibroblast Growth Factor Receptor 63 biologic therapeutics 63 receptor tyrosine kinase inhibitor 63 Aurora Kinase 63 orally bioavailable 63 Atiprimod 63 therapeutic monoclonal antibody 63 tubulin inhibitor 63 monoclonal anti 63 mGlu2 3 63 HuMax EGFr 63 pan HDAC inhibitor 62 histone deacetylase 62 riociguat 62 RNAi therapeutic targeting 62 PEG SN# 62 Carfilzomib 62 Tarvacin TM 62 TLR8 agonist 62 rBChE 62 SAR# [004] 62 anti CD3 antibody 62 estrogen receptor beta 62 lucinactant 62 preclinical pharmacokinetic 62 mimetic compounds 62 cMET 62 afamelanotide 62 novel prodrug 62 genomic biomarker 62 VEGF inhibitors 62 antisense oligonucleotide 62 orally dosed 62 generation antisense inhibitor 62 mTOR inhibitors 62 antibody MT# 62 gastrointestinal stromal tumors GIST 62 inhibit metastasis 62 IMA# 62 ALV# 62 Hedgehog antagonist 62 angiogenesis inhibitor 62 SGLT 62 enzastaurin 62 vivo validation 62 EP #R 62 polycythemia vera PV 62 antiangiogenic agent 62 multikinase inhibitor 62 RNAi therapeutic targeting PCSK9 62 immunotoxin 62 radiation sensitizer 62 Azedra 62 thymidylate synthase TS 62 2DG 62 gastric carcinoma 62 phosphate S1P 62 CA9 SCAN 62 EGFR HER 62 GW# [003] 62 bortezomib Velcade 62 4E BP1 62 XL# inhibits 62 Trofex 62 FGFR 62 HGS ETR2 62 Th2 cytokines 62 Akt inhibitor 62 USL# 62 SCIB1 62 potent inducer 62 phosphatidylserine PS targeting 62 Safinamide 62 telomerase activator 62 proteasome inhibitors 62 neurite outgrowth 62 chimeric monoclonal antibody 62 mTOR mammalian target 62 molecular determinants 62 PSN# [002] 62 HDACi 62 Tie2 62 CRMD# 61 #ME# 61 CG# [003] 61 annexin 61 Clusterin 61 NF kB pathway 61 alvespimycin 61 potent anticancer 61 CDK inhibitors 61 Archexin 61 VitiGam 61 targets Galectin receptors 61 histamine dihydrochloride 61 Hsp# Inhibitor 61 LAF# 61 antiangiogenesis 61 HIF 1α 61 Angiolix 61 Curaxin 61 cathepsins 61 Vitaxin 61 HuLuc# 61 MGd 61 HSP# inhibitor 61 PI3K delta 61 CBLC# 61 Phase IIb clinical trials 61 ALK inhibitor 61 pharmacodynamic markers 61 imatinib Gleevec ® 61 investigational monoclonal antibody 61 immune modulation 61 humanised monoclonal antibody 61 PI3K inhibitor 61 ARRY # 61 ERK pathway 61 HCV protease inhibitors 61 TNFa 61 DACH platinum 61 Pathway Inhibitor 61 JAK1 61 mitotic kinesins 61 antiapoptotic 61 siRNA therapeutics 61 DNA intercalator 61 DXL# 61 PXD# 61 Smac mimetics 61 novel immunotherapeutic 61 metastatic malignant 61 microtubule inhibitor 61 gastrin 61 heparanase 61 oral JAK1 61 peptidomimetic 61 kinase inhibitor 61 phosphoprotein 61 Kinase Inhibitor 61 AP# [003] 61 ZOLINZA 61 trastuzumab DM1 T DM1 61 ATL# [002] 61 tyrosine kinase inhibitor 61 anti CD3 61 chemosensitivity 61 PDE4 inhibitor 61 Phase #b/#a clinical 61 cellular immunotherapy 61 prodrugs 61 sodium glucose cotransporter 61 immune modulator 61 pancreatic alpha 61 nucleotide analog 61 antitumor efficacy 61 JAK3 inhibitor 61 pharmacological chaperone 61 refractory acute myeloid 61 receptor inhibitor 61 CCR2 61 Liposomal 61 IAP inhibitors 61 targeting PCSK9 61 PI3 kinase 61 PDGF receptor 61 imatinib resistance 61 EGS# 61 antisense inhibitor 61 mimetics 61 systemic RNAi 61 AQ4N 61 PDX pralatrexate 61 antitumoral 61 cetuximab Erbitux 61 Pazopanib 61 Monoclonal antibody 61 PI3K/Akt pathway inhibitor 61 TÎ ² 4 61 mitogenic 61 TLR antagonists 61 SIRT2 61 Panzem R 61 epothilone 61 immunotherapeutic vaccine 61 tumor hypoxia 61 Fibrillex 61 GRN#L 61 lymphoid malignancies 61 PTP 1B 61 immunoregulatory 61 tipifarnib 61 erlotinib Tarceva 61 oxysterols 61 inhibiting enzymes 61 radiotherapeutic 61 Curaxin CBLC# 61 redox active 61 novel histone deacetylase 61 taxane resistant 61 NeoLipid TM 61 chemokine receptors 61 Anavex #-# 61 peptidic 61 Thiovir 61 tanespimycin 61 acetonide FA 61 enkephalin 61 upregulates 60 humanized anti 60 Darinaparsin 60 corticosteroid dexamethasone 60 antithrombotic agents 60 varespladib 60 #D#C# 60 Fc fusion protein 60 APOPTONE 60 Abiraterone acetate 60 CEQ# 60 antimitotic 60 intranasal formulation 60 Hsp# inhibition 60 immunomodulatory properties 60 FGFs 60 investigational hepatitis C 60 Afatinib 60 MEK inhibitor 60 druggable target 60 triphendiol 60 immunomodulation 60 Bruton tyrosine kinase Btk 60 FOLOTYN ® 60 malignant ascites 60 IGF IR 60 calcitonin gene related 60 antimetastatic 60 SNT MC# 60 2 methoxyestradiol 60 peptibody 60 CB2 receptor 60 fibrotic disorders 60 phase IIb clinical 60 EGF receptor 60 anticancer activity 60 Interferon alpha 60 anticancer agent 60 MAPK pathway 60 potent inhibitors 60 anticancer therapy 60 neurotrophic 60 proteasome inhibition 60 epothilones 60 secreted protein 60 Solorel TM 60 TRO# 60 inhibitory effects 60 personalized immunotherapy 60 neratinib 60 VEGF receptor inhibitor 60 dasatinib Sprycel 60 humanized antibody 60 ESBA# 60 aurora kinase inhibitor 60 potent inhibitor 60 prostaglandin synthesis 60 PCK# 60 efaproxiral 60 neuronal nicotinic receptors NNRs 60 Denufosol 60 Diamyd ® 60 inhibit tumor angiogenesis 60 Reverse Cholesterol Transport 60 PARP inhibition 60 TLR9 agonists 60 MVA BN 60 chemokine receptor 60 tafamidis 60 PLX cells 60 Pentraxin 2 60 myeloproliferative disorders 60 phosphatidylinositol 3 60 Fibroblast 60 PI3 kinase inhibitor 60 Sym# 60 Symadex 60 reslizumab 60 inverse agonist 60 XmAb# 60 Troxatyl TM 60 potent antiproliferative 60 polysaccharide polymer 60 thymosin beta 4 60 anticancer therapeutics 60 TLE3 60 VEGF receptor 60 hyaluronidase enzyme 60 5 HT2C 60 Upregulation 60 Anticalins ® 60 E2F Decoy 60 CCR1 60 ruxolitinib 60 Tyrima 60 MAP kinase 60 Protein Kinase C 60 antitumor effect 60 NP2 Enkephalin 60 novel anticancer 60 BAY #-# 60 inhaled iloprost 60 Xanafide 60 atherosclerosis regression 60 QuadraSphere 60 THR beta agonist 60 potent suppressor 60 otelixizumab 60 non nucleoside inhibitor 60 antiproliferative 60 EGFR pathway 60 telomerase inhibitor 60 TOCOSOL 60 Collategene 60 HDL Selective Delipidation 60 thromboxane A2 60 HDAC Inhibitor 60 murine model 60 humanised antibody 60 alkylating agent 60 BIBW 60 trial evaluating PRX# 60 preclinically 60 gefitinib Iressa 60 Apoptone 60 glucagon receptor 60 tiapamil 60 NS5A 60 JAK inhibitors 60 sulodexide 60 Fodosine 60 chemopreventive 60 Immunotherapeutic 60 serine protease 60 mTOR kinase 60 pharmacodynamic PD 60 TransVax tm 60 TLR8 60 exocrine pancreas 60 osteogenic 60 vivo efficacy 60 Modrenal 60 CCR5 antagonist 60 anti fibrotic 60 CXCR7 60 Pimavanserin 60 zanolimumab 60 DCVax R 60 degranulation 60 metaglidasen 60 selective agonist 60 enzyme cofactor 60 LY# [002] 60 Anticalin ® 60 selective kinase inhibitor 60 reversible inhibitor 60 oral picoplatin 60 mda 7 60 highly selective inhibitor 60 incyclinide 60 CINTREDEKIN BESUDOTOX 60 protein tyrosine 60 Benlysta belimumab 60 antibody MAb 60 HER2 antibody 60 human IgG1 monoclonal 60 Cx# [002] 60 SGLT2 inhibitors 60 albumin bound paclitaxel 60 Pyridorin 60 CR# vcMMAE 60 LY# [003] 60 prognostic marker 60 epithelial tumors 60 Troxatyl 60 cyclic adenosine monophosphate cAMP 60 neuronal dysfunction 60 prolyl hydroxylase inhibitors 60 CoVal TM fusion 60 replicon 60 small molecule agonists 60 Interferon beta 60 engineered anticoagulant 60 Akt activation 60 Dasatinib 59 IRX 2 59 sorafenib Nexavar 59 forodesine 59 ALK inhibitors 59 photoprotective drug 59 Breast Cancer Assay 59 Fx #A 59 Ataluren 59 injectable formulation 59 preclinical efficacy 59 NSCLC tumors 59 hypoxia activated prodrug 59 HCV protease 59 anti angiogenic drugs 59 small molecule inhibitors 59 demonstrated antitumor activity 59 indibulin 59 5alpha reductase 59 JAK#/JAK# 59 ATIR 59 enzyme inhibitor 59 GLYX 59 epigenetic therapies 59 erythropoietic 59 Tumour Vascular Disrupting Agent 59 Neuvenge 59 Factor VEGF 59 CCR9 antagonist 59 cyclic peptide 59 Dapagliflozin 59 GRNCM1 59 pharmacodynamic biomarkers 59 P#X# 59 Aurora kinase inhibitors 59 chronic thromboembolic pulmonary 59 gastrointestinal stromal tumors GISTs 59 siRNA therapeutic 59 Phase Ib study 59 PEGylated interferon 59 Romiplostim 59 EOquin TM 59 CYT# potent vascular disrupting 59 Tyrosine Kinase Inhibitor 59 Pralatrexate 59 Cethrin R 59 prostanoid 59 KIACTA ™ 59 multicenter Phase II 59 Temsirolimus 59 induces apoptosis 59 Gleevec resistant 59 induce apoptosis 59 cytoprotective 59 Cloretazine 59 selective inhibitor 59 deacetylase inhibitors 59 oral anticancer 59 Potelligent Technology 59 immunomodulating 59 cysteamine bitartrate 59 Silodosin 59 myelofibrosis polycythemia vera 59 Nanobody 59 multiple myeloma MM 59 INCB# [001] 59 chemotherapeutic agent 59 immunomodulatory 59 topoisomerase II inhibitor 59 angiogenesis inhibition 59 Kinoid 59 MyVax R 59 ON #.Na 59 Cintredekin Besudotox 59 PPARg 59 EGFr 59 PSMA ADC 59 Bioral ® 59 volociximab 59 PKC# 59 inhibit viral replication 59 anti CD# antibody 59 YONDELIS 59 Hsp# inhibitors 59 Janus Kinase 59 Friedreich Ataxia FRDA 59 zotarolimus 59 peroxisome proliferator activated 59 ZFP Therapeutic 59 FLT3 59 phase IIb trial 59 oral antiviral 59 AT1R 59 WT1 59 radiosensitivity 59 ALB # 59 proliferative disorders 59 Smad3 59 mechanistic insights 59 Phase Ib II 59 gastric carcinomas 59 KSP inhibitor 59 humanized monoclonal antibody 59 Onalta ™ 59 GAP #B# 59 apoptotic pathway 59 prescribed proton pump 59 trastuzumab DM1 59 Panzem R NCD 59 demethylating agents 59 aerosolized KL4 surfactant 59 BZL# 59 Plicera 59 assay detects 59 antiproliferative effects 59 thetreatment 59 Elvitegravir 59 tolevamer 59 Zemiva TM 59 PI3K Akt 59 activin 59 Pertuzumab 59 inhibitor rofecoxib 59 Presents Preclinical Data 59 anticancer therapies 59 prognostic biomarker 59 hepatocellular carcinoma liver 59 Spiegelmer ® 59 Genz # 59 nitric oxide donating prostaglandin 59 orally administered inhibitor 59 Enkephalin 59 HCV polymerase 59 cardioprotective effects 59 haematological cancers 59 MyVax ® 59 histone deacetylases 59 solithromycin 59 S#P# 59 radioimmunotherapy RIT 59 lorvotuzumab mertansine 59 L BLP# 59 biologic pathway 59 sitaxsentan 59 Chemokine Receptor 59 Bafetinib 59 cyclin dependent kinase inhibitor 59 DOS# 59 inhibit KSP 59 siRNA binds 59 subtype selective 59 selective antagonist 59 Estrogen Receptor 59 peripherally acting 59 isotypes 59 radiolabeled 59 BiTE 59 Histone deacetylase 59 metalloprotease 59 neuro protective 59 investigational pan BCR 59 Flt3 59 alpha antagonist 59 inosine 59 TH# [003] 59 IL 1β 59 Actimmune ® 59 Homspera TM 59 Myolimus 59 BRAF inhibitor 59 Virulizin ® 59 cytotoxic effects 59 5 HT4 59 Azedra TM 59 synthase TS 59 hedgehog pathway 59 genotoxicity 59 Eg5 59 dihydrofolate reductase 59 inhibiting telomerase 59 BioSilicon 59 Orally administered 59 Trovax 59 RH1 59 myelin repair 59 Muraglitazar 59 androgen receptor AR 59 mGluR5 NAM 59 beta1 integrin 59 HSP# inhibitors 59 telomerase inhibitor drug 59 telomerase activation 59 CA4P 59 iroxanadine 59 Src kinase 59 beta interferons 59 cardiotoxic 59 TLR9 agonist 59 targeted nucleotide prodrug 59 SAR# [002] 59 thalidomide Thalomid 59 cetuximab Erbitux ® 59 ENTEREG ® 59 CB2 selective 59 non nucleoside HCV 59 pro angiogenic 59 multiplex assay 59 Vernakalant 59 Debio 59 Factor Receptor 59 alpha7 59 novel VDA molecule 59 coagulation cascade 59 entinostat 59 anti angiogenic agents 59 huN# DM1 59 pharmacodynamic parameters 59 nanocarrier 59 IgM antibody 59 Tarvacin 59 Topoisomerase II 59 stem cell mobilizer 59 Tanespimycin 59 ANG# 59 antifibrotic 59 MTP inhibitor 59 PEDF 59 CRAC channel 59 sodium stibogluconate 59 HQK 59 Zarnestra 58 eniluracil 58 oncogenesis 58 cancer immunotherapies 58 myeloperoxidase 58 immunotoxins 58 covalently linked 58 OX1 58 GSK3B 58 Bezielle 58 SGLT2 58 GRN# 58 induce angiogenesis 58 ONCONASE R 58 pain palliation 58 denileukin diftitox 58 Bicifadine 58 drug GAP #B# 58 BIM #A# 58 Kamada AAT 58 LNPs 58 cilengitide 58 PNP inhibitor 58 LE SN# 58 pharmacokinetic interactions 58 Biolimus A9 58 Phenoptin 58 druggable targets 58 carbohydrate polymer 58 MAXY G# 58 nutlin 58 polymerase inhibitors 58 methionine aminopeptidase 58 TXNIP 58 predictive toxicology 58 XYOTAX TM 58 AZILECT ® 58 mitochondrial toxicity 58 immune dysregulation 58 PET tracers 58 ZFP TF 58 INS# [001] 58 adult mesenchymal stem 58 Quinamed 58 teplizumab 58 PPARgamma 58 CD# expression [001] 58 Beta catenin pathway 58 optimal dosing regimens 58 MEK inhibitor RDEA# 58 c myc gene 58 IGFBP2 58 Adrian Hobden Ph.D. 58 infused intravenously 58 tenascin 58 Presents Preclinical 58 Delipidation 58 vitamin D analogs 58 cationic lipid 58 Sutent sunitinib 58 fast skeletal troponin 58 tramiprosate 58 Hedgehog inhibitor 58 synthetic siRNA 58 enzyme inhibitors 58 FK# 58 RhuDex ® 58 Hsp# inhibitor 58 HuMax CD4 58 PTHrP 58 effector function 58 Valortim R 58 AAG geldanamycin analog 58 Tarceva TM 58 LE DT 58 TRX1 58 therapeutic modality 58 anti CD# antibodies 58 IL #E 58 Aganocide ® 58 retaspimycin 58 neuroprotective properties 58 partial agonist 58 histone deacetylase inhibitors 58 GRP# 58 biodistribution 58 Insegia 58 VitiGam TM 58 CYC# 58 PEGylated 58 nAChR 58 PI3K AKT 58 UPLYSO 58 ACV1 58 pediatric acute lymphoblastic 58 Annamycin 58 CTAP# Capsules 58 tolerogenic 58 Posiphen 58 Exherin TM 58 Aurora kinase 58 MYLOTARG 58 DCCR 58 Morpholino 58 serotonin uptake 58 induced cytotoxicity 58 M2 subunit 58 GeneICE 58 small molecule modulators 58 prostatic tissue 58 GGTase 58 multitargeted 58 adipogenic 58 ENMD # 58 elotuzumab 58 butyrylcholinesterase 58 TGF Beta 58 liposome formulation 58 candidate deforolimus 58 neuroinflammation 58 oral salmon calcitonin 58 glycogen synthase kinase 58 Azacitidine 58 p# MAP kinase inhibitor 58 estrogen receptor modulators 58 TOCOSOL Camptothecin 58 Vascular Endothelial Growth 58 thyroid hormone receptor 58 Cytochrome P# 58 Bendavia 58 BAL# [001] 58 anionic backbone 58 adecatumumab MT# 58 COPREXA ™ 58 DiLA2 58 uricase 58 peptide CGRP 58 PTK# 58 seliciclib CYC# 58 Initiate Clinical Trial 58 acadesine 58 accumulate preferentially 58 airway epithelial 58 MLN# 58 ERK5 58 monoclonal antibody mAb 58 PRT# 58 Atrasentan 58 midstage trials 58 R roscovitine 58 MAPK signaling pathway 58 arterial thrombosis 58 p# MAPK 58 proteinase 58 phase Ib 58 Sphingomab TM 58 AMPK activators 58 gastric adenocarcinoma 58 NEUGENE antisense 58 Raf kinase 58 Panzem ® 58 Panzem NCD 58 Cloretazine ® 58 SMARTICLES ® 58 novel therapeutic antibodies 58 phase IIb III 58 HDAC inhibition 58 CCR9 58 Achieves Primary Endpoint 58 viral kinetics 58 gp# protein [002] 58 IMC #B 58 HDAC2 58 selectively inhibit 58 PACCE 58 EGFR receptor 58 Kevetrin ™ 58 Antisense 58 RGB # 58 matrix metalloproteases 58 CYP #A# 58 rxRNA 58 including eniluracil ADH 58 peptidic compound 58 gastrointestinal absorption 58 Spiegelmers 58 matrix metalloproteinases 58 CCX# 58 antiangiogenic 58 KL4 Surfactant 58 protein CETP 58 Maribavir 58 DCVax 58 proprietary polysaccharide 58 potently inhibits 58 glucocorticoid receptor 58 kinase pathway 58 TKM ApoB 58 BrachySil ™ 58 busulfan 58 interleukin IL -# 58 biomarker assay 58 IGF1R 58 vascular disrupting 58 resolvins 58 CCR3 58 siRNA conjugates 58 RIP1 kinase 58 Evoltra ® 58 murine models 58 Pharmacokinetics PK 58 quinone 58 HepDirect technology 58 antitumor 58 PDE7 inhibitors 58 LymphoStat B belimumab 58 IL 1ß 58 vitro assay 58 dexanabinol 58 potently inhibited 58 Genasense ® oblimersen 58 CEACAM1 58 mecamylamine 58 HCV protease inhibitor 58 BiovaxID TM 58 CINOD 58 investigational orally administered 58 immunological diseases 58 samalizumab 58 poly ADP ribose polymerase 58 SERMs 58 generation antisense 58 Aurora kinase inhibitor 58 ELACYT 58 TRIST study 58 MGCD# [001] 58 TG# [003] 58 cytokine signaling 58 5 HT2A serotonin 58 apoptosis inducing 58 EndoTAG TM -1 58 Junovan TM 58 gamma secretase inhibitor 58 Marqibo TM 58 TPI ASM8 58 OMP #M# 58 anti angiogenic therapy 58 JAK2 inhibitors 58 plasma kallikrein 58 antiangiogenic therapy 58 factor Xa inhibitors 58 deforolimus 58 SPC# [001] 58 Viprovex TM 58 VNP#M 58 Lyn kinase 58 hypoxia inducible factor 58 Parathyroid hormone 58 PKM2 58 EndoTAG TM 58 OXIGON TM 58 Initiates Clinical 58 bone morphogenic protein 58 nucleoside analog 58 brostallicin 58 costimulation 58 anti infective treatments 58 Lisofylline LSF 58 receptor antagonists 58 delta isoform